Individualized new antigen vaccine! Neo-pv-01 of neon company and opdivo show strong curative effect on three kinds of cancer

July 16, 2019 / BIOON / - Neon therapeutics is a clinical stage immunooncology company It is an industry leader in the field of new antigen targeted therapy, and is committed to the treatment of cancer by guiding the immune system to target new anti original transformation Currently, the company is using its new antigen platform to develop vaccines and T-cell therapies Recently, the company announced the top line results of nt-001, a multicenter stage IB clinical study This study evaluated the efficacy and safety of neo-pv-01, a candidate product of neon company's individualized new antigen vaccine, in combination with opdivo, a tumor immunotherapy of Bristol Myers Squibb PD-1, in the treatment of patients with advanced or metastatic melanoma, smoking related non-small cell lung cancer (NSCLC), and bladder cancer The median follow-up data of at least 12 months showed that neo-pv-01 combined with opdivo showed prolonged and continuous improvement in progression free survival (PFS) in all three different tumor types, which was superior to the single drug treatment of checkpoint inhibitors based on historical benchmark data The median follow-up time was 13.4 months in 34 patients with metastatic melanoma, 5.6 months in 27 patients with metastatic NSCLC and 5.6 months in 21 patients with metastatic bladder cancer The top line data from these 82 patients support the further development of neo-pv-01, including a randomized phase II clinical study to evaluate the efficacy of the drug in the treatment of metastatic diseases Neon Recon machine learning platform and new antigen vaccine epitope diffusion mechanism neo-pv-01 is a research personalized new antigen vaccine of neon company, which is designed and manufactured according to the unique mutation fingerprint of each patient Neo-pv-01 includes up to 20 new antigen targeting peptides selected by neon's Recon bioinformatics engine, aiming to generate an anti-tumor immune response and guide T cells to target specific new antigens in patients' tumors At present, neo-pv-01 is being evaluated and treated in a number of phase I clinical studies In addition to neo-pv-01, the company has two therapies, neo-ptc-01 and neo-sv-01 The former is a new antigen T-cell therapy for solid tumors, and the latter is a new antigen vaccine for hormone receptor positive (HR -) breast cancer Source of original text: Neon therapeutics' personal neonatigen vaccine study demands advanced progress free survival in advanced or metastatic melanoma, non small cell lung and blade cancer